Who are SEL-212 high-dose's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sel-212-high-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

SEL-212 high-dose — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SEL-212 high-dose (SEL-212 high-dose) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Uricase with immunosuppressant combination. Area: Rheumatology / Gout.

phase 3 Uricase with immunosuppressant combination Uric acid (via pegsiticase uricase enzyme) Rheumatology / Gout Small molecule Live · refreshed every 30 min

Target snapshot

SEL-212 high-dose (SEL-212 high-dose) — Swedish Orphan Biovitrum. SEL-212 is a combination therapy that pairs a uricase enzyme with an immunosuppressant to lower uric acid levels while preventing immune reactions against the enzyme.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SEL-212 high-dose TARGET	SEL-212 high-dose	Swedish Orphan Biovitrum	phase 3	Uricase with immunosuppressant combination	Uric acid (via pegsiticase uricase enzyme)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Uricase with immunosuppressant combination class)

Swedish Orphan Biovitrum · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SEL-212 high-dose — Competitive Intelligence Brief. https://druglandscape.com/ci/sel-212-high-dose. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing